Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects

Pharmacology and Therapeutics

Volumn 129, Issue 3, 2011, Pages 332-351

  Chan, Kayi Y ^a   Vermeersch, Steve ^b   De Hoon, Jan ^b   Villalón, Carlos M ^c   Maassenvandenbrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Antimigraine drugs; CGRP receptor antagonists; Migraine; Neuropeptides; Vascular side effects

Indexed keywords

1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 3,N DIMETHYL N [1 METHYL 3 (4 METHYL 1 PIPERIDINYL)PROPYL]BENZENESULFONAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 CARBAMOYLTRYPTAMINE; ANTIMIGRAINE AGENT; AS 19; BI 44370; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; GLUTAMATE RECEPTOR ANTAGONIST; LASMIDITAN; LISURIDE; METHYSERGIDE; MK 3207; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; OLCEGEPANT; PLACEBO; PNU 142633; SEROTONIN AGONIST; SUMATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; BLOOD FLOW VELOCITY; BRAIN REGION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEART HEMODYNAMICS; HUMAN; ISCHEMIA; LIVER FUNCTION TEST; LIVER TOXICITY; MIGRAINE; MYALGIA; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THROAT TIGHTNESS; VASOCONSTRICTION; VASODILATATION; XEROSTOMIA;

EID: 79551680960     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.12.001     Document Type: Review

References (327)

1. S.K. Afridi, H. Kaube, and P.J. Goadsby Glyceryl trinitrate triggers premonitory symptoms in migraineurs Pain 110 2004 675 680
2. 7-receptor agonists for the treatment of migraines CNS Neurol Disord Drug Targets 6 2007 235 237
3. 1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent autonomic responses and neuronal firing in the trigeminocervical complex Cephalalgia 29 Suppl. 1 2009 130
4. S. Akerman, D.J. Williamson, H. Kaube, and P.J. Goadsby Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels Br J Pharmacol 137 2002 62 68
5. W.K. Alderton, A.D. Angell, C. Craig, J. Dawson, E. Garvey, and S. Moncada GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo Br J Pharmacol 145 2005 301 312
6. A.R. Andersen, P. Tfelt-Hansen, and N.A. Lassen The effect of ergotamine and dihydroergotamine on cerebral blood flow in man Stroke 18 1987 120 123
7. P. Andlin-Sobocki, B. Jonsson, H.U. Wittchen, and J. Olesen Cost of disorders of the brain in Europe Eur J Neurol 12 Suppl 1 2005 1 27
8. A. Andreou, and P.J. Goadsby LY466195, a clinically active compound in the acute treatment of migraine, inhibits activation in trigeminocervical complex and ventroposteromedial thalamus after nociceptive trigeminovascular activation Cephalalgia 29 2009 133
9. A.P. Andreou, and P.J. Goadsby Therapeutic potential of novel glutamate receptor antagonists in migraine Expert Opin Investig Drugs 18 2009 789 803
10. A.P. Andreou, P.R. Holland, and P.J. Goadsby Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation Br J Pharmacol 157 2009 464 473
11. M. Anthony, H. Hinterberger, and J.W. Lance Plasma serotonin in migraine and stress Arch Neurol 16 1967 544 552
12. U. Arulmani, A. MaassenVanDenBrink, C.M. Villalón, and P.R. Saxena Calcitonin gene-related peptide and its role in migraine pathophysiology Eur J Pharmacol 500 2004 315 330
13. U. Arulmani, M.P. Schuijt, J.P.C. Heiligers, E.W. Willems, C.M. Villalón, and P.R. Saxena Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats Basic Clin Pharmacol Toxicol 94 2004 291 297
14. C. Ayata, H. Jin, C. Kudo, T. Dalkara, and M.A. Moskowitz Suppression of cortical spreading depression in migraine prophylaxis Ann Neurol 59 2006 652 661
15. M. Baun, J. Olesen, and I. Jansen-Olesen Expression studies and pharmacological characterization of VIP and PACAP receptors in the cerebral circulation of the rat Cephalalgia 29 Suppl. 1 2009 133
16. M.O. Behm, R.L. Blanchard, M.G. Murphy, J.A. Chodakewitz, J.S. Palcza, and D.E. Harris Assessment of the effect of MK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease Headache 48 2008 S39
17. D. Bell, and B.J. McDermott Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance Pharmacol Rev 48 1996 253 288
18. A. Bhardwaj, F.J. Northington, R.N. Ichord, D.F. Hanley, R.J. Traystman, and R.C. Koehler Characterization of ionotropic glutamate receptor-mediated nitric oxide production in vivo in rats Stroke 28 1997 850 856
19. M.E. Bigal, T. Kurth, H. Hu, N. Santanello, and R.B. Lipton Migraine and cardiovascular disease: possible mechanisms of interaction Neurology 72 2009 1864 1871
20. M.E. Bigal, and R.B. Lipton Overuse of acute migraine medications and migraine chronification Curr Pain Headache Rep 13 2009 301 307
21. S. Birk, J.T. Sitarz, K.A. Petersen, P.S. Oturai, C. Kruuse, and J. Fahrenkrug The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers Regul Pept 140 2007 185 191
22. R.L. Blanchard, J. Rowe, J. Palcza, T.H. Han, M.S. Forman, and W. Liu High dose telcagepant has no effect on 24-hr ambulatory blood pressure or heart rate in healthy volunteers Headache 50 2010 S35
23. B. Borroni, R. Rao, P. Liberini, E. Venturelli, M. Cossandi, and S. Archetti Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura Headache 46 2006 1575 1579
24. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery Br J Pharmacol 129 2000 501 508
25. M. Boulaksil, S.K. Winckels, M.A. Engelen, M. Stein, T.A. van Veen, and J.A. Jansen Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias Eur J Heart Fail 12 2010 913 921
26. D.S. Bredt Endogenous nitric oxide synthesis: biological functions and pathophysiology Free Radic Res 31 1999 577 596
27. 7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice Pain 141 2009 239 247
28. K.C. Brennan, L. Beltran-Parrazal, H.E. López-Valdes, J. Theriot, A.W. Toga, and A.C. Charles Distinct vascular conduction with cortical spreading depression J Neurophysiol 97 2007 4143 4151
29. E.G. Brown, C.A. Endersby, R.N. Smith, and J.C. Talbot The safety and tolerability of sumatriptan: an overview Eur Neurol 31 1991 339 344
30. R. Burstein Deconstructing migraine headache into peripheral and central sensitization Pain 89 2001 107 110
31. R. Burstein, D. Yarnitsky, I. Goor-Aryeh, B.J. Ransil, and Z.H. Bajwa An association between migraine and cutaneous allodynia Ann Neurol 47 2000 614 624
32. D.W. Busija, F. Bari, F. Domoki, and T. Louis Mechanisms involved in the cerebrovascular dilator effects of N-methyl-d-aspartate in cerebral cortex Brain Res Rev 56 2007 89 100
33. H. Cai, X. Xu, Z. Liu, Q. Wang, G. Feng, and Y. Li The effects of calcitonin gene-related peptide on bFGF and AQP4 expression after focal cerebral ischemia reperfusion in rats Pharmazie 65 2010 274 278
34. L.O. Cardell, R. Uddman, A. Luts, and F. Sundler Pituitary adenylate cyclase activating peptide (PACAP) in guinea-pig lung: distribution and dilatory effects Regul Pept 36 1991 379 390
35. C.G. Cardenas, L.P. Mar, A.V. Vysokanov, P.B. Arnold, L.M. Cardenas, and D.J. Surmeier Serotonergic modulation of hyperpolarization-activated current in acutely isolated rat dorsal root ganglion neurons J Physiol 518 Pt 2 1999 507 523
36. (1F), receptor subtype Br J Pharmacol 132 2001 991 998
37. W. Chai, S. Mehrotra, A.H.J. Danser, and R.G. Schoemaker The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts Eur J Pharmacol 531 2006 246 253
38. K.Y. Chan, R. de Vries, F.P. Leijten, H.J. Pfannkuche, A.J. van den Bogaerdt, and A.H.J. Danser Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries Eur J Pharmacol 619 2009 61 67
39. W.N. Chan, J.M. Evans, M.S. Hadley, H.J. Herdon, J.C. Jerman, and A.A. Parsons Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3, 4-dihydro-2, 2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent Bioorg Med Chem Lett 9 1999 285 290
40. K.Y. Chan, S. Gupta, R. de Vries, A.H.J. Danser, C.M. Villalón, and E. Muñoz-Islas Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model Br J Pharmacol 160 2010 1316 1325
41. Chan, K.Y., Baun, M., de Vries, R., van den Bogaerdt, A.J., Dirven, C.M.F., Danser, A.H.J., et al., in press. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia.
42. K.Y. Chan, L. Edvinsson, S. Eftekhari, P.O. Kimblad, S.A. Kane, and J. Lynch Characterization of the CGRP receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries J Pharmacol Exp Ther 334 2010 746 752
43. T. Chataigneau, and V.B. Schini-Kerth Vascular effects of ovariectomy and chronic oestrogen treatment in rats: controversy or experimental protocol diversity? Br J Pharmacol 144 2005 161 163
44. P.K. Chatterjee, N.S. Patel, A. Sivarajah, E.O. Kvale, L. Dugo, and S. Cuzzocrea GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury Kidney Int 63 2003 853 865
45. I. Christiansen, L.L. Thomsen, D. Daugaard, V. Ulrich, and J. Olesen Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura Cephalalgia 19 1999 660 667
46. J.D. Classey, Y.E. Knight, and P.J. Goadsby The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat Brain Res 907 2001 117 124
47. T.J. Coderre, and K. Yashpal Intracellular messengers contributing to persistent nociception and hyperalgesia induced by l-glutamate and substance P in the rat formalin pain model Eur J Neurosci 6 1994 1328 1334
48. A.C. Conner, D.L. Hay, S.G. Howitt, K. Kilk, U. Langel, and M. Wheatley Interaction of calcitonin-gene-related peptide with its receptors Biochem Soc Trans 30 2002 451 455
49. K.M. Connor, R.E. Shapiro, H.C. Diener, S. Lucas, J. Kost, and X. Fan Randomized, controlled trial of telcagepant for the acute treatment of migraine Neurology 73 2009 970 977
50. J. Cortijo, M. Marti-Cabrera, E. Bernabeu, T. Domenech, J. Bou, and A.G. Fernández Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies Br J Pharmacol 122 1997 1455 1463
51. S. Cuzzocrea, P.K. Chatterjee, E. Mazzon, M.C. McDonald, L. Dugo, and R. Di Paola Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis Eur J Pharmacol 453 2002 119 129
52. A. Dahl, D. Russell, R. Nyberg-Hansen, and K. Rootwelt Cluster headache: transcranial Doppler ultrasound and rCBF studies Cephalalgia 10 1990 87 94
53. C.G. Dahlöf, A.W. Hauge, and J. Olesen Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study Cephalalgia 29 Suppl 2 2009 7 16
54. T. Dalsgaard, J. Hannibal, J. Fahrenkrug, C.R. Larsen, and B. Ottesen VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries Regul Pept 110 2003 179 188
55. S. Damodaram, S. Thalakoti, S.E. Freeman, F.G. Garrett, and P.L. Durham Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling Headache 49 2009 5 20
56. R. Davis-Taber, S. Baker, S.G. Lehto, C. Zhong, C.S. Surowy, and C.R. Faltynek Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states J Pain 9 2008 449 456
57. J. De Alba, N.M. Clayton, S.D. Collins, P. Colthup, I. Chessell, and R.G. Knowles GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain Pain 120 2006 170 181
58. R. De Col, S.V. Koulchitsky, and K.B. Messlinger Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus NeuroReport 14 2003 229 232
59. J. De Hoon, C. MacLeod, J. Palcza, M. Behm, M. Depré, and I. De Lepeleire Lack of significant pharmacodynamic interaction between telcagepant 600 mg and sumatriptan 100 mg Cephalalgia 29 2009 1349
60. J.N. De Hoon, P. Pickkers, P. Smits, H.A. Struijker-Boudier, and L.M. Van Bortel Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans Clin Pharmacol Ther 73 2003 312 321
61. J.N. De Hoon, K.A. Poppe, H.H. Thijssen, H.A. Struijker-Boudier, and L.M. Van Bortel Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data Br J Clin Pharmacol 52 2001 45 51
62. 1B/1D-receptor agonists in patients with migraine headaches Clin Pharmacol Ther 68 2000 418 426
63. P. De Vries, A. Sánchez-López, D. Centurión, J.P.C. Heiligers, P.R. Saxena, and C.M. Villalón The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB224289), but not by 5-HT1D (BRL15572) receptor antagonists Eur J Pharmacol 362 1998 69 72
64. P. De Vries, C.M. Villalón, and P.R. Saxena Pharmacology of tryptans Emerging Drugs 1999 107 125
65. C. De Wit, and T.M. Griffith Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses Pflügers Arch 459 2010 897 914
66. E. Del Bene, M. Poggioni, and S. Michelacci Lisuride as a migraine prophylactic in children: an open clinical trial Int J Clin Pharmacol Res 3 1983 137 141
67. L. Dickson, and K. Finlayson VPAC and PAC receptors: from ligands to function Pharmacol Ther 121 2009 294 316
68. M. Diomedi, F. Sallustio, B. Rizzato, F. Ferrante, G. Leone, and E. Spera Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study Neurology 65 2005 919 921
69. D.W. Dodick Tonabersat for migraine prevention: new life or last gasp? Lancet Neurol 8 2009 693 695
70. D. Dodick, R.B. Lipton, V. Martin, V. Papademetriou, W. Rosamond, and A. MaassenVanDenBrink Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine Headache 44 2004 414 425
71. H. Doods, G. Hallermayer, D. Wu, M. Entzeroth, K. Rudolf, and W. Engel Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist Br J Pharmacol 129 2000 420 423
72. L. Dugo, S. Marzocco, E. Mazzon, R. Di Paola, T. Genovese, and A.P. Caputi Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation Br J Pharmacol 141 2004 979 987
73. P.L. Durham Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine Headache 48 2008 1269 1275
74. P.L. Durham, and C.V. Vause Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine CNS Drugs 24 2010 539 548
75. J. Edmeads History of migraine treatment Can J Clin Pharmacol 6 Suppl A 1999 5A 8A
76. L. Edvinsson Functional role of perivascular peptides in the control of cerebral circulation Trends Neurosci 8 1985 126 131
77. L. Edvinsson CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 155 2008 967 969
78. L. Edvinsson, R. Alm, D. Shaw, R.Z. Rutledge, K.S. Koblan, and J. Longmore Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells Eur J Pharmacol 434 2002 49 53
79. L. Edvinsson, R. Ekman, I. Jansen, A. Ottosson, and R. Uddman Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology Ann Neurol 21 1987 431 437
80. L. Edvinsson, and P.J. Goadsby Extracerebral manifestations in migraine. A peptidergic involvement? J Intern Med 228 1990 299 304
81. L. Edvinsson, and P.J. Goadsby Neuropeptides in headache Eur J Neurol 5 1998 329 341
82. L. Edvinsson, and T.W. Ho CGRP receptor antagonism and migraine Neurotherapeutics 7 2010 164 175
83. L. Edvinsson, and M. Linde New drugs in migraine treatment and prophylaxis: telcagepant and topiramate Lancet 376 2010 645 655
84. L. Edvinsson, H. Mulder, P.J. Goadsby, and R. Uddman Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide J Auton Nerv Syst 70 1998 15 22
85. L. Edvinsson, C. Owman, and N.O. Sjoberg Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study Brain Res 115 1976 377 393
86. L. Edvinsson, and P. Tfelt-Hansen The blood-brain barrier in migraine treatment Cephalalgia 28 2008 1245 1258
87. L. Edvinsson, and R. Uddman Neurobiology in primary headaches Brain Res Rev 48 2005 438 456
88. L. Edvinsson, E. Uddman, A. Wackenfors, A. Davenport, J. Longmore, and M. Malmsjo Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect Clin Sci (Lond) 109 2005 335 342
89. L. Edvinsson, K.Y. Chan, S. Eftekhari, E. Nilsson, R. de Vries, and A.H.J. Danser Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries Cephalalgia 30 2010 1233 1240
90. S. Eftekhari, C.A. Salvatore, A. Calamari, S.A. Kane, J. Tajti, and L. Edvinsson Differential distribution of calcitonin gene-related peptide (CGRP) and CGRP receptor components (CLR and RAMP1) in the human trigeminal ganglion Neuroscience 169 2010 683 696
91. J.W. Elting, G.A. Sulter, M. Kaste, K.R. Lees, H.C. Diener, and M. Hommel AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels Stroke 33 2002 2813 2818
92. 1D agonists: potential new treatment for migraine without cardiovascular side effects J Med Chem 41 1998 2180 2183
93. K.J. Escott, D.T. Beattie, H.E. Connor, and S.D. Brain Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide Brain Res 669 1995 93 99
94. M. Félétou, and P.M. Vanhoutte EDHF: an update Clin Sci (Lond) 117 2009 139 155
95. M.D. Ferrari, K.I. Roon, R.B. Lipton, and P.J. Goadsby Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials Lancet 358 2001 1668 1675
96. M.D. Ferrari, and P.R. Saxena Clinical and experimental effects of sumatriptan in humans Trends Pharmacol Sci 14 1993 129 133
97. 1F receptor agonist lasmiditan-a randomised proof-of-concept trial Cephalalgia 30 2010 1170 1178
98. M.J. Fischer, S. Koulchitsky, and K. Messlinger The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus J Neurosci 25 2005 5877 5883
99. P.A. Fowler, L.F. Lacey, M. Thomas, O.N. Keene, R.J. Tanner, and N.S. Baber The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan Eur Neurol 31 1991 291 294
100. A. Franco-Cereceda, and J.M. Lundberg Actions of calcitonin gene-related peptide and tachykinins in relation to the contractile effects of capsaicin in the guinea-pig and rat heart in vitro Naunyn-Schmiedeberg's Arch Pharmacol 337 1988 649 655
101. M.G. Garry, L.P. Walton, and M.A. Davis Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from the spinal cord is mediated by nitric oxide but not by cyclic GMP Brain Res 861 2000 208 219
102. N.J. Giffin, F. Kowacs, V. Libri, P. Williams, P.J. Goadsby, and H. Kaube Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects Cephalalgia 23 2003 287 292
103. P.J. Goadsby Migraine: emerging treatment options for preventive and acute attack therapy Expert Opin Emerg Drugs 11 2006 419 427
104. P.J. Goadsby Recent advances in understanding migraine mechanisms, molecules and therapeutics Trends Mol Med 13 2007 39 44
105. P.J. Goadsby Cortical spreading depression-better understanding and more questions. Focus on "distinct vascular conduction with cortical spreading depression" J Neurophysiol 97 2007 3827
106. P.J. Goadsby Emerging therapies for migraine Nat Clin Pract Neurol 3 2007 610 619
107. P.J. Goadsby Headache Neurotherapeutics 7 2010 149 152
108. P.J. Goadsby, and J.D. Classey Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow Brain Res 875 2000 119 124
109. 1F receptor inhibitory effects on trigeminal neurons with craniovascular input Neuroscience 122 2003 491 498
110. P.J. Goadsby, and L. Edvinsson The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats Ann Neurol 33 1993 48 56
111. P.J. Goadsby, L. Edvinsson, and R. Ekman Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system Ann Neurol 23 1988 193 196
112. P.J. Goadsby, L. Edvinsson, and R. Ekman Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 28 1990 183 187
113. P.J. Goadsby, M.D. Ferrari, A. Csanyi, J. Olesen, J.G. Mills, and T.O.N.S.G. Tonabersat Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis Cephalalgia 29 2009 742 750
114. P.J. Goadsby, R.B. Lipton, and M.D. Ferrari Migraine-current understanding and treatment N Engl J Med 346 2002 257 270
115. E.M. Golding, and T.E. Kepler Role of estrogen in modulating EDHF-mediated dilations in the female rat middle cerebral artery Am J Physiol Heart Circ Physiol 280 2001 H2417 H2423
116. (1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial Lancet 358 2001 1230 1234
117. A. Gorji, D. Scheller, H. Straub, F. Tegtmeier, R. Kohling, and J.M. Hohling Spreading depression in human neocortical slices Brain Res 906 2001 74 83
118. J.R. Graham, and H.G. Wolff Mechanisms of migraine headache and action of ergotamine tartrate Arch Neurol Psyquiat 39 1938 737 763
119. S. Gulbenkian, O. Saetrum Opgaard, R. Ekman, N. Costa Andrade, J. Wharton, and J.M. Polak Peptidergic innervation of human epicardial coronary arteries Circ Res 73 1993 579 588 (Pubitemid 23238743)
120. S. Gulbenkian, R. Uddman, and L. Edvinsson Neuronal messengers in the human cerebral circulation Peptides 22 2001 995 1007
121. S. Gupta, S. Mehrotra, C.J. Avezaat, C.M. Villalón, P.R. Saxena, and A. MaassenVanDenBrink Characterisation of CGRP receptors in the human isolated middle meningeal artery Life Sci 79 2006 265 271
122. S. Gupta, S. Mehrotra, C.M. Villalón, I.M. Garrelds, R. de Vries, and J.P. van Kats Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity Eur J Pharmacol 530 2006 107 116
123. B. Gómez-Mancilla, N.R. Cutler, M.T. Leibowitz, E.L. Spierings, J.A. Klapper, and S. Diamond Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine Cephalalgia 21 2001 727 732
124. N. Hadjikhani, M. Sánchez Del Rio, O. Wu, D. Schwartz, D. Bakker, and B. Fischl Mechanisms of migraine aura revealed by functional MRI in human visual cortex Proc Natl Acad Sci USA 98 2001 4687 4692
125. 1B receptors causes hypothermia in the guinea pig Eur J Pharmacol 331 1997 169 174
126. S. Halpain, C.M. Wieczorek, and T.C. Rainbow Localization of l-glutamate receptors in rat brain by quantitative autoradiography J Neurosci 4 1984 2247 2258
127. J.M. Hansen, J. Sitarz, S. Birk, A.M. Rahmann, P.S. Oturai, and J. Fahrenkrug Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers Cephalalgia 26 2006 992 1003
128. J.E. Hardebo, T. Wieloch, and J. Kahrstrom Excitatory amino acids and cerebrovascular tone Acta Physiol Scand 136 1989 483 485
129. Y. Hattori, M. Watanabe, T. Iwabe, E. Tanaka, M. Nishi, and J. Aoyama Administration of MK-801 decreases c-Fos expression in the trigeminal sensory nuclear complex but increases it in the midbrain during experimental movement of rat molars Brain Res 1021 2004 183 191
130. A.W. Hauge, M.S. Asghar, H.W. Schytz, K. Christensen, and J. Olesen Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study Lancet Neurol 8 2009 718 723
131. G.G. Hesketh, J.E. Van Eyk, and G.F. Tomaselli Mechanisms of gap junction traffic in health and disease J Cardiovasc Pharmacol 54 2009 263 272
132. D. Hewitt, S. Aurora, D. Dodick, P. Goadsby, J. Ge, and R. Bachman Efficacy and tolerability of the CGRP receptor antagonist MK-3207 for the acute treatment of migraine: a single attack randomized double-blind placebo-controlled adaptive dose ranging trial Cephalalgia 29 2009 1350 1351
133. S. Hirose, S. Momosaki, K. Sasaki, R. Hosoi, K. Abe, and A. Gee De-coupling of blood flow and metabolism in the rat brain induced by glutamate Ann Nucl Med 23 2009 293 300
134. L. Hjorth Lassen, H. Klingenberg Iversen, and J. Olesen A dose-response study of nitric oxide synthase inhibition in different vascular beds in man Eur J Clin Pharmacol 59 2003 499 505
135. A.P. Ho, B.R. Chaitman, M.O. Behm, J.F. Rowe, J.S. Palcza, and I. Laethem Telcagepant does not reduce exercise tolerance in patients with exercise induced myocardial ischemia Headache 50 2010 s1
136. T.W. Ho, M.D. Ferrari, D.W. Dodick, V. Galet, J. Kost, and X. Fan Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial Lancet 372 2008 2115 2123
137. T.W. Ho, L.K. Mannix, X. Fan, C. Assaid, C. Furtek, and C.J. Jones Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine Neurology 70 2008 1304 1312
138. A.P. Ho, C.G.H. Dahlöf, S.D. Silberstein, J.R. Saper, M. Ashina, and J.T. Kost Randomized, controlled trial of telcagepant over four migraine attacks Cephalalgia 30 2010 1443 1457
139. A. Hoffmann, T. Gloe, U. Pohl, and S. Zahler Nitric oxide enhances de novo formation of endothelial gap junctions Cardiovasc Res 60 2003 421 430
140. K.L. Hoskin, D.C. Bulmer, and P.J. Goadsby Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME Neurosci Lett 266 1999 173 176
141. K.L. Hoskin, H. Kaube, and P.J. Goadsby Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study Brain 119 Pt 1 1996 249 256
142. K. Hoye, B.E. Laurijssens, L.O. Harnisch, C.K. Twomey, R.M. Dixon, and A. Kirkham Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine Cephalalgia 29 2009 132
143. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, and E.J. Mylecharane International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol Rev 46 1994 157 203
144. R. Huang, A. Karve, I. Shah, M.C. Bowers, D.J. DiPette, and S.C. Supowit Deletion of the mouse alpha-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia-reperfusion injury Am J Physiol Heart Circ Physiol 294 2008 H1291 H1297
145. A. Huang, D. Sun, E.G. Shesely, E.M. Levee, A. Koller, and G. Kaley Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice Am J Physiol Heart Circ Physiol 282 2002 H429 H436
146. P.P. Humphrey The discovery and development of the triptans, a major therapeutic breakthrough Headache 48 2008 685 687
147. P.P.A. Humphrey, and W. Feniuk Mode of action of the anti-migraine drug sumatriptan Trends Pharmacol Sci 12 1991 444 446
148. J.A. Jansen, T.A. van Veen, J.M. de Bakker, and H.V. van Rijen Cardiac connexins and impulse propagation J Mol Cell Cardiol 48 2010 76 82
149. I. Jansen-Olesen, S. Gulbenkian, U. Engel, M. Cunha e Sa, and L. Edvinsson Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries Peptides 25 2004 2105 2114
150. I. Jansen-Olesen, L. Jorgensen, U. Engel, and L. Edvinsson In-depth characterization of CGRP receptors in human intracranial arteries Eur J Pharmacol 481 2003 207 216
151. I. Jansen-Olesen, A. Mortensen, and L. Edvinsson Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase Cephalalgia 16 1996 310 316
152. T.S. Jensen, and T.L. Yaksh The antinociceptive activity of excitatory amino acids in the rat brainstem: an anatomical and pharmacological analysis Brain Res 569 1992 255 267
153. K.W. Johnson, D.K. Dieckman, and L.A. Phebus GLUR5 antagonists as novel migraine therapies Cephalalgia 21 2001 268
154. K.W. Johnson, E.S. Nisenbaum, M.P. Johnson, D.K. Dieckman, A. Clemens-Smith, and E.R. Siuda Innovative drug development for headache disorders: glutamate J. Olesen, N.M. Ramadan, Frontiers in Headache Research 2008 New York Oxford 185 194
155. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs NeuroReport 8 1997 2237 2240
156. M.G. Jones, I. Lever, S. Bingham, S. Read, S.B. McMahon, and A. Parsons Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat Cephalalgia 21 2001 643 655
157. M.A. Kai-Kai, and R. Howe Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat Histochem J 23 1991 171 179
158. G. Kallner, A. Gonon, and A. Franco-Cereceda Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig Cardiovasc Res 38 1998 493 499 (Pubitemid 28294168)
159. P. Kameritsch, A. Hoffmann, and U. Pohl Opposing effects of nitric oxide on different connexins expressed in the vascular system Cell Commun Adhes 10 2003 305 309
160. P. Kameritsch, N. Khandoga, W. Nagel, C. Hundhausen, D. Lidington, and U. Pohl Nitric oxide specifically reduces the permeability of Cx37-containing gap junctions to small molecules J Cell Physiol 203 2005 233 242
161. K. Kapoor, U. Arulmani, J.P.C. Heiligers, I.M. Garrelds, E.W. Willems, and H. Doods Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs Br J Pharmacol 140 2003 329 338
162. H. Kaube, J. Herzog, T. Kaufer, M. Dichgans, and H.C. Diener Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine Neurology 55 2000 139 141
163. W. Kennedy, C.C. Li, J. Palcza, A. Gipson, W. Denney, and T. Han Blockade of capsaicin-induced dermal vasodilation (CIDV) by MK-3207, a calcitonin-gene related peptide (CGRP) receptor antagonist for acute treatment of migraine Cephalalgia 29 2009 1357
164. R.W. Kimball, A.P. Friedman, and E. Vallejo Effect of serotonin in migraine patients Neurology 10 1960 107 111
165. A.G. Kleber, and Y. Rudy Basic mechanisms of cardiac impulse propagation and associated arrhythmias Physiol Rev 84 2004 431 488
166. M. Knutsson, and L. Edvinsson Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia NeuroReport 13 2002 507 509
167. S. Koulchitsky, M.J. Fischer, R. De Col, P.M. Schlechtweg, and K. Messlinger Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat-possible implications for the pathophysiology of headaches J Neurophysiol 92 2004 1320 1328
168. C. Kruuse, L.L. Thomsen, S. Birk, and J. Olesen Migraine can be induced by sildenafil without changes in middle cerebral artery diameter Brain 126 2003 241 247
169. Y.W. Kwan, R.M. Wadsworth, and K.A. Kane Effects of neuropeptide Y and calcitonin gene-related peptide on sheep coronary artery rings under oxygenated, hypoxic and simulated myocardial ischaemic conditions Br J Pharmacol 99 1990 774 778
170. G.A. Lambert, K.L. Hoskin, and A.S. Zagami Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular first-order synapse Neuropharmacology 47 2004 92 105
171. K.G. Lamping, D.W. Nuno, E.G. Shesely, N. Maeda, and F.M. Faraci Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice Am J Physiol Heart Circ Physiol 279 2000 H1906 H1912
172. L.H. Lassen, M. Ashina, I. Christiansen, V. Ulrich, and J. Olesen Nitric oxide synthase inhibition in migraine Lancet 349 1997 401 402 (Pubitemid 27077677)
173. L.H. Lassen, P.A. Haderslev, V.B. Jacobsen, H.K. Iversen, B. Sperling, and J. Olesen CGRP may play a causative role in migraine Cephalalgia 22 2002 54 61
174. L. Lassen, B. Sperling, A. Andersen, and J. Olesen The effect of i.v. L-NG methylarginine hydrochloride (L-NMMA: 546 C88) on basal and acetazolamide (Diamox) induced changes of blood velocity in cerebral arteries and regional cerebral blood flow in man Cephalalgia 25 2005 344 352
175. M. Lauritzen, and A.J. Hansen The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression J Cereb Blood Flow Metab 12 1992 223 229
176. M. Lauritzen, T. Skyhoj Olsen, N.A. Lassen, and O.B. Paulson Changes in regional cerebral blood flow during the course of classic migraine attacks Ann Neurol 13 1983 633 641 (Pubitemid 13103461)
177. N.P. Lee, and C.Y. Cheng Nitric oxide and cyclic nucleotides: their roles in junction dynamics and spermatogenesis Adv Exp Med Biol 636 2008 172 185
178. J.K. Lennerz, V. Ruhle, E.P. Ceppa, W.L. Neuhuber, N.W. Bunnett, and E.F. Grady Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution J Comp Neurol 507 2008 1277 1299
179. D. Levy, R. Burstein, V. Kainz, M. Jakubowski, and A.M. Strassman Mast cell degranulation activates a pain pathway underlying migraine headache Pain 130 2007 166 176
180. D. Levy, R. Burstein, and A.M. Strassman Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine Ann Neurol 58 2005 698 705
181. D. Li, N.S. Li, Q.Q. Chen, R. Guo, P.S. Xu, and H.W. Deng Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts Regul Pept 147 2008 4 8
182. Y.J. Li, and J. Peng The cardioprotection of calcitonin gene-related peptide-mediated preconditioning Eur J Pharmacol 442 2002 173 177
183. A.S. Link, A. Kuris, and L. Edvinsson Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system J Headache Pain 9 2008 5 12
184. Y. Liu, J. Broman, and L. Edvinsson Central projections of the sensory innervation of the rat middle meningeal artery Brain Res 1208 2008 103 110
185. J. Longmore, Z. Razzaque, D. Shaw, A.P. Davenport, J. Maguire, and J.D. Pickard Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors Br J Clin Pharmacol 46 1998 577 582
186. R. Lu, Y.J. Li, and H.W. Deng Evidence for calcitonin gene-related peptide-mediated ischemic preconditioning in the rat heart Regul Pept 82 1999 53 57
187. (1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs Eur J Pharmacol 623 2009 96 102
188. 1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis J Cardiovasc Pharmacol 53 2009 474 479
189. (1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats NeuroReport 12 2001 1589 1591
190. A. MaassenVanDenBrink, D.J. Duncker, and P.R. Saxena Migraine headache is not associated with cerebral or meningeal vasodilatation- A 3 T magnetic resonance angiography study Brain 132 2009
191. A. MaassenVanDenBrink, M. Reekers, W.A. Bax, M.D. Ferrari, and P.R. Saxena Coronary side-effect potential of current and prospective antimigraine drugs Circulation 98 1998 25 30
192. A. MaassenVanDenBrink, R.W.M. van den Broek, R. de Vries, N. Upton, A.A. Parsons, and P.R. Saxena The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan Cephalalgia 20 2000 538 545
193. T. Mabuchi, N. Shintani, S. Matsumura, E. Okuda-Ashitaka, H. Hashimoto, and T. Muratani Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain J Neurosci 24 2004 7283 7291
194. 7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells Neuropharmacology 49 2005 40 47
195. J. Mao, D.D. Price, J. Zhu, J. Lu, and D.J. Mayer The inhibition of nitric oxide-activated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat Pain 72 1997 355 366
196. 1D receptor agonist effects of dihydroergotamine J. Olesen, M.A. Moskowitz, Experimental Headache Models 1995 Lippincott-Raven Philadelphia 163 167
197. F. Martínez, J. Castillo, J.R. Rodríguez, R. Leira, and M. Noya Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks Cephalalgia 13 1993 89 93 (Pubitemid 23116117)
198. N.T. Mathew, S. Landy, S. Stark, G.E. Tietjen, F.J. Derosier, and J. White Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life Headache 49 2009 971 982
199. 1D receptor agonist PNU-142633 Cephalalgia 22 2002 799 806
200. M.C. McDonald, M. Izumi, S. Cuzzocrea, and C. Thiemermann A novel, potent and selective inhibitor of the activity of inducible nitric oxide synthase (GW274150) reduces the organ injury in hemorrhagic shock J Physiol Pharmacol 53 2002 555 569
201. K. Messlinger, A. Suzuki, M. Pawlak, A. Zehnter, and R.F. Schmidt Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat Br J Pharmacol 129 2000 1397 1404
202. D.D. Mitsikostas, M. Sánchez del Rio, C. Waeber, Z. Huang, F.M. Cutrer, and M.A. Moskowitz Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis Br J Pharmacol 127 1999 623 630 (Pubitemid 29276647)
203. D.D. Mitsikostas, M. Sánchez del Rio, C. Waeber, M.A. Moskowitz, and F.M. Cutrer The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis Pain 76 1998 239 248
204. T. Miura, T. Miki, and T. Yano Role of the gap junction in ischemic preconditioning in the heart Am J Physiol Heart Circ Physiol 298 2010 H1115 H1125
205. D.T. Monaghan, R.J. Bridges, and C.W. Cotman The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system Annu Rev Pharmacol Toxicol 29 1989 365 402
206. S. Moncada, and E.A. Higgs Molecular mechanisms and therapeutic strategies related to nitric oxide FASEB J 9 1995 1319 1330
207. M.A. Moskowitz Neurogenic inflammation in the pathophysiology and treatment of migraine Neurology 43 Suppl 3 1993 S16 S20
208. M.A. Moskowitz, J.F. Reinhard Jr., J. Romero, E. Melamed, and D.J. Pettibone Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 2 1979 883 885
209. K.W. Muir Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists Curr Opin Pharmacol 6 2006 53 60
210. E. Müller-Schweinitzer Ergot Alkaloids in Migraine: it the Effect via 5-HT Receptors? J. Olesen, P.R. Saxena, 5-Hydroxytryptamine mechanisms in primary headaches 1992 Raven New York 297 304
211. E. Müller-Schweinitzer, and H. Weidmann Basic pharmacological properties B. Berde, H.O. Schild, Ergot Alkaloids and Related Compounds 1978 Springer Verlag Berlin, Heidelberg, New York 87 232
212. M.F. Murphy, S.J. Mellberg, N.M. Kurtz, and E.A. Graham AMPA/kainate receptor antagonist Tezampanel is effective in treating acute migraine Headache 48 2008 8
213. J.I. Nagy, F.E. Dudek, and J.E. Rash Update on connexins and gap junctions in neurons and glia in the mammalian nervous system Brain Res Rev 47 2004 191 215
214. S. Nakata, M. Tsutsui, H. Shimokawa, O. Suda, T. Morishita, and K. Shibata Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms Circulation 117 2008 2211 2223
215. S. Nawate, M. Fukao, I. Sakuma, T. Soma, K. Nagai, and O. Takikawa Reciprocal changes in endothelium-derived hyperpolarizing factor- and nitric oxide-system in the mesenteric artery of adult female rats following ovariectomy Br J Pharmacol 144 2005 178 189
216. B. Nellgard, and T. Wieloch NMDA-receptor blockers but not NBQX, an AMPA-receptor antagonist, inhibit spreading depression in the rat brain Acta Physiol Scand 146 1992 497 503
217. 1F receptor agonist lasmiditan Cephalalgia 30 2010 1159 1169
218. T. Nilsson, J. Longmore, D. Shaw, E. Pantev, J.A. Bard, and T. Branchek Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques Eur J Pharmacol 372 1999 49 56
219. T.P. Obrenovitch, and E. Zilkha Inhibition of cortical spreading depression by L-701, 324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex Br J Pharmacol 117 1996 931 937
220. M. Ohsawa, G.C. Brailoiu, M. Shiraki, N.J. Dun, K. Paul, and L.F. Tseng Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse Pain 100 2002 27 34
221. J. Olesen The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache Pharmacol Ther 120 2008 157 171
222. J. Olesen Nitric oxide-related drug targets in headache Neurotherapeutics 7 2010 183 190
223. J. Olesen, R. Burstein, M. Ashina, and P. Tfelt-Hansen Origin of pain in migraine: evidence for peripheral sensitisation Lancet Neurol 8 2009 679 690
224. J. Olesen, H.C. Diener, I.W. Husstedt, P.J. Goadsby, D. Hall, and U. Meier Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N Engl J Med 350 2004 1104 1110
225. J. Olesen, L. Friberg, T.S. Olsen, H.K. Iversen, N.A. Lassen, and A.R. Andersen Timing and topography of cerebral blood flow, aura, and headache during migraine attacks Ann Neurol 28 1990 791 798
226. J. Olesen, and P.J. Goadsby Synthesis of migraine mechanisms J. Olesen, P.j. Goadsby, N. Ramadan, P. Tfelt-Hansen, K.M.A. Welch, The Headaches 2006 Lippincott Williams & Wilkins Philadelphia
227. J. Olesen, P.J. Goadsby, N. Ramadan, P. Tfelt-Hansen, and K.M.A. Welch J. Olesen, P.J. Goadsby, N. Ramadan, P. Tfelt-Hansen, K.M.A. Welch, The Headaches 2006 Lippincott Williams & Wilkins Philadelphia 1 1169
228. M.L. Oshinsky, and J. Luo Neurochemistry of trigeminal activation in an animal model of migraine Headache 46 Suppl 1 2006 S39 S44
229. J.R. Ostergaard, E. Mikkelsen, and B. Voldby Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery Cephalalgia 1 1981 223 228
230. J.P. Ottervanger, H.J. Paalman, G.L. Boxma, and B.H. Stricker Transmural myocardial infarction with sumatriptan Lancet 341 1993 861 862
231. A. Ottosson, and L. Edvinsson Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide Cephalalgia 17 1997 166 174
232. J.E. Palmer, F.L. Guillard, B.E. Laurijssens, A.L. Wentz, R.M. Dixon, and P.M. Williams A selective iNOS inhibitor, in the treatment of acute migraine Cephalalgia 29 2009 124
233. D.V. Paone, A.W. Shaw, D.N. Nguyen, C.S. Burgey, J.Z. Deng, and S.A. Kane Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R, 6 S)-6-(2, 3-difluorophenyl)-2-oxo-1- (2, 2, 2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2, 3-dihydro-1 H-imidazo[4, 5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974) J Med Chem 50 2007 5564 5567
234. A.A. Parsons, S. Bingham, P. Raval, S. Read, M. Thompson, and N. Upton Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes Br J Pharmacol 132 2001 1549 1557
235. L.S. Patel, C.K. Mitchell, W.P. Dubinsky, and J. O'Brien Regulation of gap junction coupling through the neuronal connexin Cx35 by nitric oxide and cGMP Cell Commun Adhes 13 2006 41 54
236. S.J. Peroutka Neurogenic inflammation and migraine: implications for the therapeutics Mol Interv 5 2005 304 311
237. K.A. Petersen, L.H. Lassen, S. Birk, L. Lesko, and J. Olesen BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation Clin Pharmacol Ther 77 2005 202 213
238. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine Life Sci 61 1997 2117 2126
239. P.A. Pierce, G.X. Xie, S.J. Peroutka, and J.D. Levine Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation Reg Anesth 21 1996 219 225
240. M.A. Pollack, and J.H. French Hypothesis: glutamic acid in migraine Headache 15 1975 114 147
241. D.R. Poyner Calcitonin gene-related peptide: multiple actions, multiple receptors Pharmacol Ther 56 1992 23 51
242. A. Rahmann, T. Wienecke, J.M. Hansen, J. Fahrenkrug, J. Olesen, and M. Ashina Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine Cephalalgia 28 2008 226 236
243. N.M. Ramadan, and T.M. Buchanan New and future migraine therapy Pharmacol Ther 112 2006 199 212
244. 1F receptor agonists in acute migraine treatment: a hypothesis Cephalalgia 23 2003 776 785
245. S.J. Read, M.I. Smith, A.J. Hunter, N. Upton, and A.A. Parsons SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat Cephalalgia 20 2000 92 99
246. C.P. Regan, G.L. Stump, S.A. Kane, and J.J. Lynch Jr. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis J Pharmacol Exp Ther 328 2009 571 578
247. A.K. Rehni, T.G. Singh, A.S. Jaggi, and N. Singh Pharmacological preconditioning of the brain: a possible interplay between opioid and calcitonin gene related peptide transduction systems Pharmacol Rep 60 2008 904 913
248. U. Reuter, H. Bolay, I. Jansen-Olesen, A. Chiarugi, M. Sanchez del Rio, and R. Letourneau Delayed inflammation in rat meninges: implications for migraine pathophysiology Brain 124 2001 2490 2502
249. P. Roffey, M. Mikhail, and D. Thangathurai NMDA receptor blockade prevents nitroglycerin-induced headaches Headache 41 2001 733
250. J.F. Rothrock, K.R. Mar, T.L. Yaksh, A. Golbeck, and A.C. Moore Cerebrospinal fluid analyses in migraine patients and controls Cephalalgia 15 1995 489 493
251. J.J. Rozniecki, V. Dimitriadou, M. Lambracht-Hall, X. Pang, and T.C. Theoharides Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo Brain Res 849 1999 1 15
252. I. Ruiz de Velasco, N. Gonzalez, Y. Etxeberria, and J.C. Garcia-Monco Quality of life in migraine patients: a qualitative study Cephalalgia 23 2003 892 900
253. O. Saetrum Opgaard, P. Hasbak, R. de Vries, P.R. Saxena, and L. Edvinsson Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae Eur J Pharmacol 397 2000 373 382
254. Y. Sahara, N. Noro, Y. Iida, K. Soma, and Y. Nakamura Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons J Neurosci 17 1997 6611 6620
255. T.E. Salt Glutamate receptor functions in sensory relay in the thalamus Philos Trans R Soc Lond B Biol Sci 357 2002 1759 1766
256. C.A. Salvatore, J.C. Hershey, H.A. Corcoran, J.F. Fay, V.K. Johnston, and E.L. Moore Pharmacological characterization of MK-0974 [N-[(3R, 6 S)-6-(2, 3-difluorophenyl)-2-oxo-1-(2, 2, 2-trifluoroethyl)azepan-3- yl]-4-(2-oxo-2, 3-dihydro-1 H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carbox amide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine J Pharmacol Exp Ther 324 2008 416 421
257. C.N. Sang, N.M. Ramadan, R.G. Wallihan, A.S. Chappell, F.G. Freitag, and T.R. Smith LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine Cephalalgia 24 2004 596 602
258. J.R. Saper, and S. Silberstein Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine Headache 46 Suppl 4 2006 S171 S181
259. 1B/1D receptor agonists in the acute treatment of migraines J. Olesen, P.J. Goadsby, N.M. Ramadan, P. Tfelt-Hansen, K.M.A. Welch, The Headaches 2006 Lippincott Williams and Wilkins Philadelphia 469 503
260. G.G. Schoonman, J. van der Grond, C. Kortmann, R.J. van der Geest, G.M. Terwindt, and M.D. Ferrari Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3 T magnetic resonance angiography study Brain 131 2008 2192 2200
261. M. Schurks, P.M. Rist, M.E. Bigal, J.E. Buring, R.B. Lipton, and T. Kurth Migraine and cardiovascular disease: systematic review and meta-analysis BMJ 339 2009 3914
262. H.W. Schytz, S. Birk, T. Wienecke, C. Kruuse, J. Olesen, and M. Ashina PACAP38 induces migraine-like attacks in patients with migraine without aura Brain 132 2009 16 25
263. N. Sekiguchi, H. Kanatsuka, K. Sato, Y. Wang, K. Akai, and T. Komaru Effect of calcitonin gene-related peptide on coronary microvessels and its role in acute myocardial ischemia Circulation 89 1994 366 374
264. N.J. Severs, A.F. Bruce, E. Dupont, and S. Rothery Remodelling of gap junctions and connexin expression in diseased myocardium Cardiovasc Res 80 2008 9 19
265. N.J. Severs, S.R. Coppen, E. Dupont, H.I. Yeh, Y.S. Ko, and T. Matsushita Gap junction alterations in human cardiac disease Cardiovasc Res 62 2004 368 377
266. Y.T. Shen, J.J. Mallee, L.K. Handt, D.B. Gilberto, J.J. Lynch Jr., and R.J. Hargreaves Effects of inhibition of alpha-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure J Cardiovasc Pharmacol 42 2003 656 661
267. Y.T. Shen, T.J. Pittman, P.S. Buie, D.L. Bolduc, S.A. Kane, and K.S. Koblan Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system J Pharmacol Exp Ther 298 2001 551 558
268. 1F receptor agonist LY334370 Cephalalgia 19 1999 851 858
269. F. Sicuteri Prophylactic and therapeutic properties of 1-methyllysergic acid butanolamide in migraine Int Arch Allergy Appl Immunol 15 1959 300 307
270. F. Sicuteri, A. Testi, and B. Anselmi Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks Int Arch Allergy Appl Immunol 19 1961 55 58
271. S.D. Silberstein The pharmacology of ergotamine and dihydroergotamine Headache 37 Suppl 1 1997 S15 S25
272. S.D. Silberstein Tonabersat, a novel gap-junction modulator for the prevention of migraine Cephalalgia 29 Suppl 2 2009 28 35
273. S.D. Silberstein, and D.C. McCrory Ergotamine and dihydroergotamine: history, pharmacology, and efficacy Headache 43 2003 144 166
274. S.D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs Topiramate in migraine prevention: results of a large controlled trial Arch Neurol 61 2004 490 495 (Pubitemid 38923736)
275. S.D. Silberstein, J. Schoenen, H. Gobel, H.C. Diener, A.H. Elkind, and J.A. Klapper Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine Cephalalgia 29 Suppl 2 2009 17 27
276. S.D. Silberstein, and W.B. Young Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology Neurology 45 1995 577 584
277. S.R. Sinclair, S.A. Kane, B.J. Van der Schueren, A. Xiao, K.J. Willson, and J. Boyle Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974) Br J Clin Pharmacol 69 2010 15 22
278. M.I. Smith, S.J. Read, W.N. Chan, M. Thompson, A.J. Hunter, and N. Upton Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453 Cephalalgia 20 2000 546 553
279. R.J. Storer, and P.J. Goadsby Trigeminovascular nociceptive transmission involves N-methyl-d-aspartate and non-N-methyl-d-aspartate glutamate receptors Neuroscience 90 1999 1371 1376
280. Y.O. Taiwo, P.H. Heller, and J.D. Levine Mediation of serotonin hyperalgesia by the cAMP second messenger system Neuroscience 48 1992 479 483
281. J. Tajti, R. Uddman, and L. Edvinsson Neuropeptide localization in the "migraine generator" region of the human brainstem Cephalalgia 21 2001 96 101
282. S.J. Tallaksen-Greene, A.B. Young, J.B. Penney, and A.J. Beitz Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat Neurosci Lett 141 1992 79 83
283. F. Tao, Y.X. Tao, C. Zhao, S. Dore, W.J. Liaw, and S.N. Raja Differential roles of neuronal and endothelial nitric oxide synthases during carrageenan-induced inflammatory hyperalgesia Neuroscience 128 2004 421 430
284. C. Tassorelli, and S.A. Joseph Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat Brain Res 682 1995 167 181
285. C. Tassorelli, and S.A. Joseph NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration Brain Res 695 1995 37 44
286. S.J. Tepper, and C. Cleves Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine Curr Opin Investig Drugs 10 2009 711 720
287. P. Tfelt-Hansen The effect of ergotamine on the arterial system in man Acta Pharmacol Toxicol (Copenh) 59 Suppl 3 1986 1 30
288. P. Tfelt-Hansen, I.L. Kanstrup, N.J. Christensen, and K. Winkler General and regional haemodynamic effects of intravenous ergotamine in man Clin Sci (Lond) 65 1983 599 604
289. P. Tfelt-Hansen, and L. Paalzow Intramuscular ergotamine: plasma levels and dynamic activity Clin Pharmacol Ther 37 1985 29 35
290. P. Tfelt-Hansen, P.R. Saxena, C. Dahlöf, J. Pascual, M. Lainez, and P. Henry Ergotamine in the acute treatment of migraine: a review and European consensus Brain 123 Pt 1 2000 9 18
291. M. Toriello, A. Oterino, J. Pascual, J. Castillo, R. Colas, and A. Alonso-Arranz Lack of association of endothelial nitric oxide synthase polymorphisms and migraine Headache 48 2008 1115 1119
292. M. Tsutsui Neuronal nitric oxide synthase as a novel anti-atherogenic factor J Atheroscler Thromb 11 2004 41 48
293. J.F. Tvedskov, H.K. Iversen, and J. Olesen A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine Cephalalgia 24 2004 875 882
294. R. Uddman, L. Edvinsson, R. Ekman, T. Kingman, and J. McCulloch Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P Neurosci Lett 62 1985 131 136
295. R. Uddman, P.J. Goadsby, I. Jansen, and L. Edvinsson PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow J Cereb Blood Flow Metab 13 1993 291 297
296. R. Uddman, J. Tajti, M. Hou, F. Sundler, and L. Edvinsson Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2 Cephalalgia 22 2002 112 116
297. 1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs Naunyn- Schmiedeberg's Arch Pharmacol 370 2004 46 53
298. B.J. Van der Schueren, R. Blanchard, M.G. Murphy, J. Palcza, I. De Lepeleire, and A. Van Hecken Effect of MK-0974, an oral CGRP antagonist, on the hemodynamic response to sublingual nitroglycerin. Headache Headache 48 2008 S63 S64
299. B.J. Van der Schueren, J.N. de Hoon, F.H. Vanmolkot, A. Van Hecken, M. Depre, and S.A. Kane Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging Br J Clin Pharmacol 64 2007 580 590
300. B.J. Van der Schueren, M.W. Lunnon, B.E. Laurijssens, F. Guillard, J. Palmer, and A. Van Hecken Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 49 2009 281 290
301. B.J. Van der Schueren, A. Rogiers, F.H. Vanmolkot, A. Van Hecken, M. Depre, and S.A. Kane Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model J Pharmacol Exp Ther 325 2008 248 255
302. F.H. Vanmolkot, and J.N. de Hoon Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform Clin Pharmacol Ther 80 2006 85 94
303. F.H. Vanmolkot, J.N. de Hoon, P. Barrington, R.W. Peck, N.S. Dallow, and P.M. Williams Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques Eur J Clin Pharmacol 58 2002 303 308
304. D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, and O. Wurtz Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery Pharmacol Rev 61 2009 283 357
305. D. Vaughan, J. Speed, R. Medve, and J.S. Andrews Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers Clin Ther 32 2010 146 160
306. R. Verheggen, K. Bumann, and A.J. Kaumann BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37) Br J Pharmacol 136 2002 120 126
307. C.M. Villalón, and D. Centurión Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications Naunyn-Schmiedeberg's Arch Pharmacol 376 2007 45 63
308. 7 receptor Br J Pharmacol 120 1997 1319 1327
309. C.M. Villalón, D. Centurión, L.F. Valdivia, P. de Vries, and P.R. Saxena Migraine: pathophysiology, pharmacology, treatment and future trends Curr Vasc Pharmacol 1 2003 71 84
310. 2-adrenoceptors Br J Pharmacol 126 1999 585 594
311. C.M. Villalón, and J. Olesen The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs Pharmacol Ther 124 2009 309 323
312. W.H. Visser, R.H. de Vriend, M.W. Jaspers, and M.D. Ferrari Sumatriptan in clinical practice: a 2-year review of 453 migraine patients Neurology 47 1996 46 51
313. C. Waeber, and M.A. Moskowitz Migraine as an inflammatory disorder Neurology 64 2005 S9 S15
314. M. Wahl, L. Schilling, A.A. Parsons, and A. Kaumann Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression Brain Res 637 1994 204 210
315. E.A. Wammes-van der Heijden, H. Rahimtoola, H.G. Leufkens, C.C. Tijssen, and A.C. Egberts Risk of ischemic complications related to the intensity of triptan and ergotamine use Neurology 67 2006 1128 1134
316. 7 receptor reduces CGRP release in an experimental model for migraine Headache 50 2010 579 587
317. E.P. Wei, M.A. Moskowitz, P. Boccalini, and H.A. Kontos Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles Circ Res 70 1992 1313 1319
318. B. Weiss, A. Alt, A.M. Ogden, M. Gates, D.K. Dieckman, and A. Clemens-Smith Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo J Pharmacol Exp Ther 318 2006 772 781
319. T.M. Williams, C.A. Stump, D.N. Nguyen, A.G. Quigley, I.M. Bell, and S.N. Gallicchio Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead Bioorg Med Chem Lett 16 2006 2595 2598
320. H.G. Wolff Headache and cranial arteries Trans. Assoc. Am. Physicians 53 1938 193 198
321. S. Wolfrum, J. Nienstedt, M. Heidbreder, K. Schneider, P. Dominiak, and A. Dendorfer Calcitonin gene related peptide mediates cardioprotection by remote preconditioning Regul Pept 127 2005 217 224
322. J. Wu, L. Fang, Q. Lin, and W.D. Willis Fos expression is induced by increased nitric oxide release in rat spinal cord dorsal horn Neuroscience 96 2000 351 357
323. J. Wu, L. Fang, Q. Lin, and W.D. Willis Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin Pain 94 2001 47 58
324. 1 receptor signaling Mol Pain 16 2008 4 12
325. H.L. Xu, E. Galea, R.A. Santizo, V.L. Baughman, and D.A. Pelligrino The key role of caveolin-1 in estrogen-mediated regulation of endothelial nitric oxide synthase function in cerebral arterioles in vivo J Cereb Blood Flow Metab 21 2001 907 913
326. J. Yao, N. Hiramatsu, Y. Zhu, T. Morioka, M. Takeda, and T. Oite Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells J Am Soc Nephrol 16 2005 58 67
327. D. Yarnitsky, I. Goor-Aryeh, Z.H. Bajwa, B.I. Ransil, F.M. Cutrer, and A. Sottile 2003 Wolff Award: possible parasympathetic contributions to peripheral and central sensitization during migraine Headache 43 2003 704 714